SOUTH SAN FRANCISCO, Calif., Jan. 18, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that REZLIDHIA™ (olutasidenib) has been added by the National Comprehensive Cancer Network® (NCCN®) to the latest NCCN Clinical Practice Guidelines in Oncology (NCCN...
News Ticker
- [ March 29, 2023 ] Layoffs hit private gene therapy startups, migraine biotech Satsuma as industry squeeze doesn’t let up News
- [ March 29, 2023 ] SIMPLETHERAPY® ANNOUNCES ACQUISITION OF PHYSMETRICS AND HALCYON BEHAVIORAL News
- [ March 29, 2023 ] SimX Awarded U.S. Air Force Contract to Develop VR Medical Support Training Simulations for Aeromedical Evacuation and Critical Care Air Transport Training News
- [ March 29, 2023 ] Assay Development, Research Associate – Adela, Inc. – Foster City, CA San Francisco Biotech Jobs
- [ March 29, 2023 ] Biomea goes for $125M offering after early diabetes data nearly doubled stock price News
Copyright © 2022 Biotech Networks, LLC
